Age at diagnosis of type 2 diabetes and cardiovascular risk factor profile: A pooled analysis

Table 1 Summary of studies included in the pooled dataset

Study name	Aim	Eligible age range (yr)	Exclusion criteria1	Clinical Trials.gov Registration Number	Ongoing/completed
CODEC	Observational study to investigate the effect of chronotype on glycaemic controls in adults with T2DM	18-75	N/A	NCT02973412	Ongoing
LYDIA	Randomised active-comparator trial to investigate the effect of liraglutide compared to sitagliptin on cardiac structure and function in younger adults with T2DM	18-60	Treatment with insulin, SGLT-2 inhibitors, GLP-1 receptor agonists of DPP-4 inhibitors; Active cardiovascular disease, including history of myocardial infarction within the past 6 mo and/or heart failure	NCT02043054	Completed
EXPEDITION	Observational study to phenotype younger adults with T2DM	18-40	N/A	N/A	Completed
DIASTOLIC	Randomised controlled trial to compare diet and exercise interventions to standard care in adults with T2DM	18-65	Current treatment with more than three glucose-lowering medications or insulin; Stroke, peripheral vascular disease, atrial fibrillation, heart failure/disease, angina	NCT02590822	Completed
PREDICT	Observational study to investigate the prevalence and determinants of subclinical cardiovascular dysfunction in adults with T2DM	18-75	Stroke, symptomatic peripheral vascular disease, atrial fibrillation, history of heart failure, history of myocardial infarction, moderate or severe heart valve disease, angina	NCT03132129	Ongoing

¹Criteria related to cardiovascular complications or medications relevant to this analysis.

T2DM: Type 2 diabetes mellitus; SGLT-2: Sodium-glucose cotransporter-2; GLP-1: Glucagon-like peptide 1; DPP-4: Dipeptidyl peptidase-4.